| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The compound does not have a well-defined pharmacological target in the context of drug development. It is the disulfide dimer of N-acetylcysteine and functions as an immunomodulator. It modulates contact sensitivity and delayed-type hypersensitivity reactions in rodents. The compound has immunosuppressant properties.
|
|---|---|
| ln Vitro |
D-7193 is a potent modulator of contact sensitivity and delayed-type hypersensitivity reactions. It exhibits immunomodulatory activity and has been investigated for its potential as an immunosuppressant. The compound is the disulfide dimer of N-acetylcysteine, which suggests it may have antioxidant properties related to its ability to modulate redox balance.
|
| ln Vivo |
N,N'-diacetyl-L-cystine (DiNAC; 0-973.11 μg/kg; oral; daily; for 12 weeks; WHHL rabbits) treatment decreases plasma lipid levels without altering thoracic aortic atherosclerosis by 50% [1].
D-7193 is orally active and has been shown to modulate contact sensitivity and delayed-type hypersensitivity reactions in rodents. It has immunosuppressant properties. The compound has been investigated for the treatment of asthma. It is a potent modulator of immune responses in vivo. |
| Enzyme Assay |
In vitro enzymatic or receptor binding assays are not well-documented for D-7193. As the disulfide dimer of N-acetylcysteine, it may be evaluated for its ability to modulate redox balance and immune cell function. The compound's purity and identity can be confirmed using HPLC and NMR analysis.
|
| Cell Assay |
In vitro cell-based assays for D-7193 may involve the use of immune cells to assess its immunomodulatory effects. The compound's ability to modulate contact sensitivity and delayed-type hypersensitivity reactions suggests effects on T cell function. However, specific cell-based assay protocols are not well-documented.
|
| Animal Protocol |
Animal/Disease Models: Male hereditary hyperlipidemia (WHHL) rabbit (10-22 weeks) [1]
Doses: 0 μg/kg, 9.73 μg/kg or 973.11 μg/kg Route of Administration: po (po (oral gavage)) Routine; 12-week Experimental Results: 50% reduction in thoracic aortic atherosclerosis without affecting plasma lipid levels. D-7193 is administered orally in rodent models to evaluate its immunomodulatory effects. It modulates contact sensitivity and delayed-type hypersensitivity reactions. The compound has been investigated for the treatment of asthma. Efficacy is assessed by measuring immune response parameters and symptom improvement. |
| ADME/Pharmacokinetics |
D-7193 is an orally active compound. It has a molecular weight of 324.37 and a molecular formula of C10H16N2O6S2. The compound is soluble in DMSO. It is the disulfide dimer of N-acetylcysteine. The compound should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for D-7193. The compound is for research use only and is not intended for human therapeutic use. As the disulfide dimer of N-acetylcysteine, it is expected to have a safety profile similar to N-acetylcysteine, which is generally well-tolerated. However, specific toxicity data is not available.
|
| References |
[1]. Wågberg M, et al. N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis. J Pharmacol Exp Ther. 2001 Oct;299(1)
[2]. Särnstrand B, et al. N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther. 1999 Mar;288(3):1174-84. |
| Additional Infomation |
D-7193 (N,N'-Diacetyl-L-cystine, DiNAC) is the disulfide dimer of N-acetylcysteine. It is a potent, orally active modulator of contact sensitivity and delayed-type hypersensitivity reactions in rodents. The compound has immunosuppressant properties and has been investigated for the treatment of asthma. It has a CAS number of 5545-17-5 and a molecular weight of 324.37. It is also known by the synonyms D-7042 and D7042. The compound is for research use only and has not been approved for clinical use.
|
| Molecular Formula |
C10H16N2O6S2
|
|---|---|
| Molecular Weight |
324.37
|
| Exact Mass |
324.044
|
| CAS # |
5545-17-5
|
| PubChem CID |
6995101
|
| Appearance |
White to light brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
715.5±60.0 °C at 760 mmHg
|
| Melting Point |
55-72ºC
|
| Flash Point |
386.5±32.9 °C
|
| Vapour Pressure |
0.0±5.0 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
0.46
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
20
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(N[C@H](C(O)=O)CSSC[C@H](NC(C)=O)C(O)=O)=O
|
| InChi Key |
YTPQSLLEROSACP-YUMQZZPRSA-N
|
| InChi Code |
InChI=1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)/t7-,8-/m0/s1
|
| Chemical Name |
(2R)-2-acetamido-3-[[(2R)-2-acetamido-2-carboxyethyl]disulfanyl]propanoic acid
|
| Synonyms |
D 7042; D-7193; D-7042
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~385.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
